Relationship between sex hormone levels, bone mineral density and bone turnover markers in healthy moroccan men: a cross-sectional study

Aissam El Maataoui1,2, Asmae Benghabrite2, Abdellah El Maghraoui3, Layachi Chabraoui4, Zhor Ouzzif1

1Mohamed V Souissi University, Faculty of Medicine and Pharmacy, Biochemistry Department at the Military Hospital, Rabat, Morocco, 2Morocco Ministry of Health, Rabat, Morocco, 3Mohamed V Souissi University, Faculty of Medicine and Pharmacy, Rheumatology Department at the Military Hospital, Rabat, Morocco, 4Mohamed V Souissi University, Faculty of Medicine and Pharmacy, Biochemistry Department at the Ibn Sina Hospital, Rabat, Morocco

Corresponding author: Aissam El Maataoui, Biochemistry Department, Centre Hospitalier Universitaire Ibn Rochd Casablanca, Morocco

Key words: Male osteoporosis, sex hormones, vitamin D, Bone remodeling markers

Received: 03/01/2015 - Accepted: 26/10/2015 - Published: 02/11/2015

Abstract

Introduction: Gonadal steroid hormones play a crucial role during skeletal growth and maturation in both men and women. The aim of this study is to evaluate the relationship of sex hormone levels, bone mineral density and biochemical markers of bone turnover in healthy Moroccan men.

Methods: 142 Moroccan men who had no previous diagnosis of osteoporosis were enrolled prospectively in this cross-sectional study between December 2009 and August 2010. Also, subjects were excluded from the study if they had conditions affecting bone metabolism. Different biochemical parameters were assayed: Testosterone, Estradiol, sex hormone binding globulin, Osteocalcin, vitamin D, crosslaps, intact parathyroid hormone and alkaline phosphatase. Dual-energy X-ray absorptiometry was used to measure the Bone mineral density (BMD) (g/cm²).

Results: In this study, among the 142 Moroccan men, 29 (20.1%) had densitometry osteoporosis and the prevalence of vitamin D insufficiency was 94%. No correlation was found between Estradiol, Testosterone and bone mineral density but we found significant differences in the levels of Estradiol between patients with osteoporosis, osteopenia and normal patients. Bone mineral density at the lumbar spine was negatively correlated to hormone-binding globulin and positively correlated to free androgen index, free estrogen index and the Body mass index. BMD at the total hip was positively correlated to free androgen index, Body mass index and negatively correlated to sex hormone binding globulin, alkaline phosphatase, intact parathyroid hormone, osteocalcin, Crosslaps and age.

Conclusion: Our study showed that increasing age, intact parathyroid hormone and alkaline phosphatase levels and decreasing body mass index were the most important independent factors associated to the presence of a low BMD at the total hip. Increasing body mass index and free androgen index level were the most important independent factors associated to the presence of a low BMD at the lumbar spine. The combination of variable that best predicted the male osteoporosis is age, body mass index, alkaline phosphatase and cigarette smoking.

Pan African Medical Journal. 2015; 22:206 doi:10.11604/pamj.2015.22.206.6066

This article is available online at: http://www.panafrican-med-journal.com/content/article/22/206/full/

© Aissam El Maataoui et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pan African Medical Journal – ISSN: 1937-8688 (www.panafrican-med-journal.com)
Published in partnership with the African Field Epidemiology Network (AFENET). (www.afenet.net)
Introduction

Osteoporosis is a metabolic bone disorder characterized by low bone mass and micro-architectural deterioration, with a subsequent increase in bone fragility and susceptibility to fracture [1]. It affects 13% of Caucasian men older than 50 years (versus 40% in women) and a 15% lifetime risk of osteoporotic fractures in the same age group [2]. Gonadal steroid hormones play a crucial role during skeletal growth and maturation in both men and women [3]. In fact, hypogonadism is a well recognized risk factor for osteoporosis in aging men, and it is found in 10% to 15% of cases [4, 5]. Also, most cohort studies indicate that estrogen concentrations are associated with bone mineral density (BMD) and bone turnover as well as bone loss in aging men [4, 5]. This correlation between Estradiol (E) and bone remodeling markers has been proven by treatment of elderly men with an aromatase inhibitor resulted in significant increase in bone resorption, together with decreases in bone formation markers [6, 7]. Sex hormone-binding globulin (SHBG) is a plasma glycoprotein that binds to sex steroids, thereby regulating their bioavailability [8], and the link between SHBG, BMD and bone remodeling markers should be given a careful attention. Also, vitamin D (25(OH)D3) deficiency includes secondary hyperparathyroidism, accelerated bone loss, increased bone turnover, osteoporosis and fractures. The aim of this study was to evaluate the relationship between sex hormone levels, biochemical markers of bone turnover and BMD in a population of asymptomatic men.

Methods

Subjects

This was a cross-sectional study conducted from December 2009 to August 2010. Men were recruited prospectively through advertisements and “word of mouth”. Men who volunteered to participate in the study were enrolled after taking an informed and written consent. One hundred and forty two consecutive men who had no previous diagnosis of osteoporosis took part in the study; all subjects were screened using a detailed questionnaire, history, behaviors and physical examination. Subjects were excluded from the study if they had conditions affecting bone metabolism, such as diseases of kidney, liver, parathyroid, thyroid, diabetes mellitus, hyperprolactinemia, rheumatoid arthritis, ankylosing spondylitis, malabsorption syndromes, malignant tumors, hematologic diseases, or previous pathological fractures. Subjects were also excluded if they had been receiving corticosteroids, thyroid hormone, fluoride, bisphosphonate, calcitonin, thiazide diuretics, barbiturates, antiseizure medications, 25(OH)D3 or calcium-containing drugs. Our institutional review board approved this study. The procedures of the study were in accordance with the Declaration of Helsinki, and local ethics committee approval was obtained for the study. Each participant completed a standardized questionnaire designed to document putative risk factors of osteoporosis. Height and weight were measured in our rheumatology center before DXA measurement, in light indoor clothes without shoes. Body mass index (BMI) was calculated by dividing weight in kilograms by height in meters squared.

BMD measurement

Bone mineral density was determined by a Lunar Prodigy Vision DXA system (Lunar Corp., Madison, WI). The DXA scans were obtained by standard procedures supplied by the manufacturer for scanning and analysis. All BMD measurements were carried out by 2 experienced technicians. Daily quality control was carried out by measurement of a lunar phantom. At the time of the study, phantom measurements showed stable results. The phantom precision expressed as the coefficient of variation percentage was 0.08 %. Moreover, reproducibility has been assessed by the same 2 technicians in clinical practice and showed a smallest detectable difference of 0.04 g/cm² (spine) and 0.02 (hips). Patient BMD was measured at the lumbar spine and at the femurs (i.e., femoral neck and total hip).

Biological measurements

All subjects had fasting blood taken in the morning. The samples were frozen and stored at -20°C and subsequently thawed and analyzed in one batch. Serum Testosterone (T), Estradiol (E), Vitamin D (25(OH)D3), sex hormone binding globulin (SHBG), Osteocalcin (OC), and Crosslaps (β-CTX), intact parathyroid hormone (PTH) were measured using electrochemiluminescence immunoassay (ECLIA) technique (Cobas e601, Roche Diagnostics GmbH, Mannheim, Germany). Alkaline phosphatase (ALP) was measured by (Dimension® RxL Max® Integrated Chemistry System of Siemens). All the laboratory tests were subject to validation using National External Quality Assurance Schemes. The free androgen index (FAI), having been shown to be more sensitive for identifying subjects with abnormal androgen status than total or free testosterone. Free androgen index (FAI= Total testosterone/SHBG x 100) was calculated from the ratio of serum T to SHBG to give an estimate of the free circulating concentration. Similarly, the free estradiol index (FEI= Total E/SHBG * 100) was calculated from the ratio of serum E to SHBG.

Statistical analysis

Results are presented as means (SD) and categorical variables are expressed as frequencies. To compare normal patients, patients with osteopenia and osteoporosis, chi-square test and ANOVA were used firstly. Correlations between continuous variables were calculated using Pearson correlation coefficients. Potential risk factors were entered to a stepwise conditional binary regression analysis and the resulted odds ratios with 95% confidence intervals were reported. Logistic-regression models were used to analyze the most important factors related to the presence of osteoporosis. The level for significance was taken as p ≤0.05. Excel 2007 and SPSS 15.0 were used for statistical analysis.

Results

In this cohort of 142 men, the mean ± SD (range) age and Body mass index were 63.3±8.7 years and 26.42±4.20 kg/m², respectively. Based on the diagnostic criteria of osteoporosis (T-score below -2.5 at the lumbar spine, the femoral neck or the total hip site) 44 subjects were diagnosed as normal (30.99%), 69 as osteopenia (48.59%) and 29 as osteoporosis (20.42%). In all patients, in which we found low levels of 25(OH)D3 (the mean ± SD range) were 20.47±6.15 ng/mL. In our study, the prevalence of smoking was 52.11 % and cigarette smoking was associated with a high prevalence of osteoporosis (p=0.004), and the smokers had a high level of ALP (p=0.029) and a low total hip BMD (TH_BMD) comparing to the nonsmokers (p=0.029) group. The concentrations of the biochemical parameters were compared among the three groups (normal bone mass group, osteopenia group and osteoporosis group). The comparison result showed that the plasma levels of ALP, SHBG, and OC were significantly higher in the
Pearson correlation analysis showed significant negative correlations between the total hip BMD and the following variables ALP, PTHi, OC, β-CTX, SHBG, FAI, Age and the BMI. And positive correlations with the following variables BMI, FAI. Pearson correlation analysis showed significant positive correlations between Lumbar spine BMD and the following parameters the FAI and the BMI. And a negative correlation was found with the SHBG.

**Results of correlation analysis between sexual hormones with blood biochemical parameters, BMD, BMI and age (Table 2)**

Pearson correlation analysis showed that there were positive correlations between estradiol and the following variables β-CTX, OC, PTHi, and there were negative correlations between estradiol and the following variables T, SHBG and vitamin D. There was a significant significant positive correlation between the T and the BMI and a significant negative correlation was found with the BMI. There were significant negative correlations between the FAI and the age, and between the FEI and the age too.

**Results of correlation analysis between vitamin D with blood biochemical parameters, BMD, BMI and age (Table 2)**

There was a significant positive correlation between the 25(OH)D3 and the following parameters E, T. A significant negative correlation was found with the lumbar spine BMD.

**Multiple regression analysis with bone mineral density as dependent variable (Table 3)**

Multiple regression analysis was therefore performed to determine the combination of variables that accounted for the greatest proportion of variance in BMD at each site. PTHi, alkaline phosphatase, age and Body mass index were related to total hip BMD. BMI and free androgen index were significantly related to Lumbar spine BMD.

**Multiple logistic regressions**

To determine the combination of variables that best predicted the male osteoporosis, a multiple logistic regression analysis was performed (Table 4) and the best model comprised ALP, Age, BMI and cigarette smoking.

**Discussion**

We analyzed in this study the association between sex hormone levels, biochemical markers of bone turnover and BMD in healthy Moroccan men. We found a higher prevalence of osteoporosis (20.45%) than what was reported in the normal Moroccan population [9], and among Caucasian men older than 50 years (13%) [2], which was probably due to a hazard effect and to the small number of men enrolled in this study. Our observations in terms of BMI are very similar to those of most studies showing that lower BMI scores were associated with BMD loss [9, 10]. The BMI of the osteoporosis group was slightly lower compared with those of the osteopenia and normal groups, and these differences were significant [11]. There were negative correlations between the BMI and OC, BMI and β-CTX, BMI and T, and BMI and 25(OH)D3. Thus, high BMI was associated with low levels of bone remodeling markers, Testosterone and 25(OH)D3. Overweight may protect men against bone loss, several explanations have been proposed. First of them by increasing the amount of biologically available estrogens, in fact, estrogen is known to inhibit bone resorption by osteoclasts [12]. A larger body mass imposes a greater mechanical loading on bone and that bone mass increases to accommodate the greater load. Although smoking is often cited as a risk factor for osteoporosis, the influence of smoking on osteoporosis remains unclear. In our study the prevalence of smoking was 52.11 % and cigarette smoking is associated with a high prevalence of osteoporosis (p=0.004), and smokers had a high level of ALP (p=0.029) and a low TH_BMD comparing to nonsmokers (p=0.029). Pearson correlation analysis in the group of smokers showed that there were positive correlations between the contents of ALP and these parameters β-CTX, OC and PTHi. Thus, smoking was associated with high level of bone turnover markers.

Smoking is thought to cause low bone density through a combination of different mechanisms, smoking has been linked to a decrease in parathyroid hormone and estrogen levels as well as to an increase in the level of cortisol and adrenal androgens, changes that have been linked to an increased risk of osteoporosis [13]. Smoking reduces body mass, which is postulated to provide an osteogenic stimulus and is linked to higher BMD [14]. Smoking reduces the level of 25(OH)D3 in the body [15]. Smoking increases free radicals and oxidative stress which affects bone resorption [16]. Smokers are more likely to suffer from peripheral vascular disease, reducing blood supply to the bones [17]. Finally, there may also exist direct toxic effects of many of the constituents in tobacco smoke on bone cells [18]. Smoking is significantly associated with higher level of alkaline phosphatase in men [19]. Thus, in our study smokers had a high level of ALP (p=0.029). We do not find any significant difference in E, T levels between patients in osteoporotic group, osteopenic group and normal group nor any correlation between blood E and BMD whatever the site measured. Slemenda and al found that BMD measurements at the hip and spine correlated negatively with serum T levels (correlation coefficients varying from -0.20 to -0.28, p= 0.03-0.10) [20]. "Legrand and all" and "Lomereau and all" did not show any statistical significant difference in E levels between controls and osteoporotic patients, and the bone blood E did not correlate with spine BMD [11, 21]. In contrast, several cross-sectional studies have shown a significant correlation between E levels and bone mass in men [5, 22-24]. FAI correlated positively to BMD but greater at the lumbar spine. FEI correlated weakly to the BMD at the lumbar spine. "Gennari and all" found that the free estradiol index (FEI) correlates positively with BMD values at the femur and lumbar spine [24]. Pearson correlation analysis showed that there were positive correlations between the contents of E and these parameters PTHi, OC and β-CTX, but negative correlations between the FAI and age, FEI and age, BMI and OC, BMI and β-CTX, BMI and T. The association between E and bone resorption markers has been confirmed in another study where significant correlations were found only with markers of bone resorption (serum and urinary NTX), but not with biochemical indices of bone formation (OC) and bone alkaline phosphatase isoenzyme (BAP) [25]. Moreover, prospective studies showed that serum E was a better predictor than serum T of both the increase in bone loss in elderly men [24, 26]. In a cross-sectional study that included men and women, "Khosla and al" reported inverse correlations between urinary NTX (cross-linked N-terminal telopeptides of type I collagen), levels and both "bioavailable" E and "bioavailable" T [11]. "Szulc and al" found that only bioavailable E levels in men were negatively correlated with bone turnover, but no
associations were observed with total E, or any testosterone measure [27].

The impact of serum testosterone on bone health parameters appears less significant and uncertain [28]. The current evidence suggests that E plays a greater role in maintenance of skeletal health than testosterone, but that androgens also have direct beneficial effects on bone. Testosterone is metabolized via the cytochrome P450 aromatase enzyme complex into 17β-estradiol, and increasing evidence indicates that at least part of the effect of androgens on bone is mediated by their aromatization to estrogens [29, 30]. And the other effects of the androgens by androgen receptors are present on bone cells, and androgen receptor mediated actions on bone have been known for several years [31].

In our data SHBG was positively correlated to age and negatively correlated to BMI and BMD (lumbar spine and total hip). Thus, the concentration of SHBG rises with age and the levels of SHBG are low in obese patients and extremely high in patients with anorexia nervosa [31]. Our study and several case-control studies have demonstrated no difference in total sex steroids, but significantly higher SHBG and lower FAI in osteoporotic group [30-32]. "Legrand and al" observed higher levels of plasma SHBG in two thirds of the 80 osteoporotic patients in their study. SHBG correlated negatively with BMI at the fe malevertebral osteoporosis (r = -0.34, p < 0.01) and secondary osteoporosis (r = -0.34, p < 0.01) [21]. Likewise, "Evans and al" found a significant increase in SHBG levels in 81 men with both idiopathic osteoporosis and fractures as compared with 68 healthy controls [31]. Longitudinal study shows that SHBG correlated negatively with trabecular bone mass [32].

We defined the hypovitaminosis D as a circulating level of 25(OH)D3 below 30 ng/mL. In this study, the prevalence of hypovitaminosis D was 94%, similar to results of previous studies of vitamin D prevalence in Moroccan women. Although Morocco enjoys a sunny climate throughout the year, many factors may explain these high prevalence. It may be related to low vitamin D intake and in our country, food is not supplemented with vitamin D. Hence, cutaneous synthesis would be the major source of 25(OH)D3. This high prevalence of hypovitaminosis D was also reported in a cross-sectional study among Saudi Arabian men (87.8%) [33]. Also, we got significant positive correlation either between 25(OH)D3 levels and E, T and the BMI. 25(OH)D3 was negatively correlated to age, hence, men with low 25(OH)D3 were older and with low level of T and E. A recent randomized placebo-controlled trial by "Pilz and al" suggested that 25(OH)D3 may increase the production of T in men [34]. "David M Lee and al" in a cross-sectional study of 3369 community-dwelling men aged 40-79 years in eight European centers, 25(OH)D3 was positively associated with total and free T and negatively with E and LH in age- and centre-adjusted linear regressions, this result was in contrast to our finding for E [35]. We did not find any correlation between 25(OH)D3 and BMD, some studies found a positive relationship between serum 25(OH)D3 and BMD, but others did not find any relationship neither [36, 37]. Perhaps because of differing age, race, gender and health/nutritional status in this reported cohorts. In our data not all patients with vitamin D insufficiency (25(OH)D3 < 30 ng/l) develop secondary hyperparathyroidism but only 50%. In fact, vitamin D insufficiency and PTH over the 65 ng/l, this may be a threshold for initiating the optimal replacement therapy [38]. The TH_BMD correlate negatively with SHBG, OC, PTH, β-CTX, ALP, age and positively with FAI, BMI. The LS_BMD was negatively correlated to SHBG and positively correlated to FAI, FEI and the BMI. BMI was the best predictor of BMD at all sites. In fact, the relationship between markers of bone remodeling and BMD in men varies in the literature, it is usually weak [35, 36] but appears stronger in subjects over 50 years of age. Some authors do not find any significant relationship between such markers and BMD in men, whatever their age [39].

Our study demonstrated that increasing age, PTH and ALP levels and decreasing BMI were the most important independent factors associated with the presence of a low bone mineral density at the total hip. Increasing BMI and FAI level were the most important independent factors associated with the presence of a low bone mineral density at the lumbar spine. The best model that can predict osteoporosis in Moroccan men was the combination of the ALP, Age, BMI and cigarette smoking. Our study has strengths and limitations. All of the DXA and biochemical measurements were conducted with a single bone densitometer and a single biochemistry laboratory, with very careful quality controls in place. The main limitations lie in the cross-sectional nature of the study and in the procedures used to select subjects, who were all volunteers and ambulatory. The study population had a higher prevalence of osteoporosis which was probably due to a hazard effect.

**Conclusion**

BMI was the best predictor of BMD at all sites. Age, PTH, ALP and BMI were the best predictors at the TH_BMD and BMI, FAI were related to LS_BMD. The combination of variable that best predicted the male osteoporosis is Age, ALP, BMI and cigarette smoking. 94% of the patients in this study had a vitamin D insufficiency. Furthermore, a positive correlation was found between 25(OH)D3 and E, T and negative correlation was found with the age. However, large scale longitudinal studies are needed to further evaluate the relationship between this parameters and the BMD.

**Competing interests**

The authors declare no competing interests.

**Authors’ contributions**

All authors have made substantial contributions to the study’s conception and design, acquisition of data or analysis and interpretation of data and have been involved in drafting the manuscript or revising it critically for important intellectual content. Aissam Elmaataoui: Study design, wrote the paper, Data Collection, Data Analysis. Layachi Chabraoui: Data Analysis, Contributed to writing of paper. Asmae Benghabrite: Data Collection, Contributed to writing of paper and design of Study. Zhor Ouizif: Study design, Data analysis, contributed to writing of paper.

**Acknowledgments**

The study was founded by grants from Roche Laboratories.

**Tables**

| Table 1: Comparison between normal patients, patients with osteopenia and osteoporosis (n=142) |
| Table 2: Correlation between biochemical values and age, BMI and BMD (n=142) |
Table 3: Multiple linear regression analysis with BMD as dependent variable (n=142)

Table 4: Multiple logistic regression analysis with BMD as dependent variable (n=142)

References

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. The American journal of medicine. 1993 Jun;94(6):646-50. Google Scholar

2. Melton LJ, 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective: How many women have osteoporosis? Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 1992 Sep;7(9):1005-10. PubMed | Google Scholar

3. Briot K, Cortet B, Tremolieres F, Sutter B, Thomas T, Roux C, et al. Male osteoporosis: diagnosis and fracture risk evaluation. Joint, bone, spine : revue du rhumatisme. 2009 Mar;76(2):129-3. PubMed | Google Scholar

4. Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters and osteoporotic fractures in elderly men. Journal of bone and mineral research: the official Journal of the American Society for Bone and Mineral Research. 2000 Jul;15(7):1405-11. PubMed | Google Scholar

5. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. The Journal of clinical endocrinology and metabolism. 2000 Sep;85(9):3276-82. PubMed | Google Scholar

6. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. The Journal of clinical endocrinology and metabolism. 1989 Sep;69(3):523-7. PubMed | Google Scholar

7. Alibhai SM, Gogov S, Alibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Critical reviews in oncology/hematology. 2006 Dec;60(3):201-15. PubMed | Google Scholar

8. Silteri PK, Murai JT, Hammond GL, Nisker JA, Raymoure WJ, Kuhn RW. The serum transport of steroid hormones. Recent progress in hormone research. 1982;38:457-510. PubMed | Google Scholar

9. El Maghraoui A, Ghazi M, Gassim S, Mouchac, Ghozlan I, Noujai A, et al. Bone mineral density of the spine and femur in a group of healthy Moroccan men. Bone. 2009 May;44(5):965-. PubMed | Google Scholar

10. Cauley JA, Fullman RL, Stone KL, Zmuda JM, Bauer DC, Barrett-Connor E et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2005 Dec;16(12):1525-37. PubMed | Google Scholar

11. Lormeau C, Soudan B, d’Herbomez M, Pigyn P, Duquesnoy B, Cortet B. Sex hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis. Bone. 2004 Jun;34(6):933-9. PubMed | Google Scholar

12. Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. The Journal of clinical endocrinology and metabolism. 1998 Jul;83(7):2266-74. PubMed | Google Scholar

13. Kapoor D, Jones TH. Smoking and hormones in health and endocrine disorders. European journal of endocrinology / European Federation of Endocrine Societies. 2005 Apr;152(4):491-9. PubMed | Google Scholar

14. Daniel M, Martin AD, Drinkwater DT. Cigarette smoking, steroid hormones, and bone mineral density in young women. Calcified tissue international. 1992 Apr;50(4):300-5. PubMed | Google Scholar

15. Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. European journal of clinical nutrition. 1999 Dec;53(12):920-6. PubMed | Google Scholar

16. Duthie GG, Arthur JR, James WP. Effects of smoking and vitamin E on blood antioxidant status. The American journal of clinical nutrition. 1991 Apr;53(4 Suppl):1061S-3S. PubMed | Google Scholar

17. Vestergaard P, Mosekilde L. Fracture risk associated with smoking: a meta-analysis. Journal of internal medicine. 2003 Dec;254(6):572-83. PubMed | Google Scholar

18. Broulik PD, Jarab J. The effect of chronic nicotine administration on bone mineral content in mice. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 1993 Apr;25(4):219-21. PubMed | Google Scholar

19. Chan-Yeung M, Ferreira P, Frohlich J, Schulzer M, Tan F. The effects of age, smoking, and alcohol on routine laboratory tests. American journal of clinical pathology. 1981 Mar;75(3):320-6. PubMed | Google Scholar

20. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC. Sex steroids and bone mass in older men: Positive associations with serum estrogens and negative associations with androgens. The Journal of clinical investigation. 1997 Oct 1;100(7):1755-9. PubMed | Google Scholar

21. Legrand E, Hedde C, Gallois Y, Degasne J, Boux de Casson F, Mathieu E et al. Osteoporosis in men: a potential role for the sex hormone binding globulin. Bone. 2001 Jul;29(1):90-5. PubMed | Google Scholar

22. Ongphiphandanukul B, Rajatanavin R, Chanprasertyothon S, Piaseu N, Chalurkit L. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clinical endocrinology. 1998 Dec;49(6):803-9. PubMed | Google Scholar
23. Van Pottelbergh I, Goemaere S, Kaufman JM. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. The Journal of clinical endocrinology and metabolism. 2003 Jul;88(7):3075-81. PubMed | Google Scholar

24. Gennari L, Merlotti D, Martini G, Gonnelli S, Franci B, Campagna S et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. The Journal of clinical endocrinology and metabolism. 2003 Nov;88(11):5327-33. PubMed | Google Scholar

25. Bjornerem A, Ahmed LA, Joakimsen RM, Berntsen GK, Fonnebo V, Jorgensen L et al. A prospective study of sex steroids, sex hormone-binding globulin, and non-vertebral fractures in women and men: the Tromso Study. European journal of endocrinology / European Federation of Endocrine Societies. 2007 Jul;157(1):119-25. PubMed | Google Scholar

26. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocrine reviews. 2002 Jun;23(3):279-302. PubMed | Google Scholar

27. Szulc P, Munoz F, Clauserat B, Garnero P, Marchand F, Duboeuf F et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. The Journal of clinical endocrinology and metabolism. 2001 Jan;86(1):192-9. PubMed | Google Scholar

28. Khosla S, Melton LJ 3rd, Riggs BL. Clinical review 144: Estrogen and the male skeleton. The Journal of clinical endocrinology and metabolism. 2002 Apr;87(4):1443-50. PubMed PMID: 11932262. Epub 2002/04/05. eng. PubMed | Google Scholar

29. Vanderschueren D, Bouillon R. Androgens and bone. Calcified tissue international. 1995 May;56(5):341-6. PubMed PMID: 7621337. Epub 1995/05/01. eng. PubMed | Google Scholar

30. Hoppe E, Bouvard B, Royer M, Audran M, Legrand E. Sex hormone-binding globulin in osteoporosis. Joint, bone, spine : revue du rhumatisme. 2010 Jul;77(4):306-12. PubMed | Google Scholar

31. Evans SF, Davie MW. Low body size and elevated sex-hormone binding globulin distinguish men with idiopathic vertebral fracture. Calcified tissue international. 2002 Jan;70(1):9-15. PubMed | Google Scholar

32. Nyquist F, Gardsell P, Sernbo I, Jeppsson JO, Johnell O. Assessment of sex hormones and bone mineral density in relation to occurrence of fracture in men: a prospective population-based study. Bone. 1998 Feb;22(2):147-51. PubMed | Google Scholar

33. Ardawi MS, Sbibani AM, Bakhsh TM, Qari MH, Maimani AA. High prevalence of vitamin D deficiency among healthy Saudi Arabian men: relationship to bone mineral density, parathyroid hormone, bone turnover markers, and lifestyle factors. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012 Feb;23(2):675-86. PubMed | Google Scholar

34. Plz S, Frisch S, Koertke H, Kuhn J, Dreier J, Obermayer-Pietsch B et al. Effect of vitamin D supplementation on testosterone levels in men. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2011 Mar;43(3):223-5. PubMed | Google Scholar

35. Lee DM, Tajar A, Pye SR, Boonen S, Vanderschueren D, Bouillon R et al. Association of hypogonadism with vitamin D status: the European Male Ageing Study. European journal of endocrinology / European Federation of Endocrine Societies. 2012 Jan;166(1):77-85. PubMed | Google Scholar

36. Bischoff-Ferrari HA, Zhang Y, Kiel DP, Felson DT. Positive association between serum 25-hydroxyvitamin D level and bone density in osteoarthritis. Arthritis and rheumatism. 2005 Dec 15;53(6):821-6. PubMed | Google Scholar

37. Cooper L, Clifton-Bligh PB, Nery ML, Figtree G, Twigg S, Hibbert E et al. Vitamin D supplementation and bone mineral density in early postmenopausal women. The American journal of clinical nutrition. 2003 May;77(5):1324-9. PubMed | Google Scholar

38. Sahota O, Mundey MK, San P, Godber IM, Lawson N, Hosking DJ. The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone. 2004 Jul;35(1):312-9. PubMed | Google Scholar

39. Wishart JM, Need AG, Horowitz M, Morris HA, Nordin BE. Effect of age on bone density and bone turnover in men. Clinical endocrinology. 1995 Feb;42(2):141-6. PubMed | Google Scholar
| Table 1: comparison between normal patients, patients with osteopenia and osteoporosis (n=142) |
|---------------------------------|-----------------|-----------------|-----------------|-------|-------|-------|-------|
|                                 | Normal (n= 44)  | Osteopenia (n=69) | Osteoporosis (n=29) | p    | p₁   | p₂   | p₃   |
| Age (years): m (SD)             | 60.87 (8.487)   | 63.42 (8.38)     | 66.93 (8.71)     | 0.012 | NS   | 0.009 | NS   |
| BMI (kg/m²): m (SD)             | 28.20 (3.93)    | 26.08 (4.26)     | 24.41 (3.87)     | <0.001 | NS   | <0.001 | 0.021 |
| PTHi (pg/ml): m (SD)            | 65.48 (30.88)   | 59.11 (21.73)    | 82.57 (53.19)    | 0.007 | 0.005 | NS   | NS   |
| ALP (U/L): m (SD)               | 82.67 (21.13)   | 88.62 (21.15)    | 107.21 (32.34)   | <0.001 | 0.002 | <0.001 | 0.573 |
| SHBG (nmol/L): m (SD)           | 48.77 (19.93)   | 58.73 (25.23)    | 68.23 (34.75)    | 0.007 | NS   | 0.006 | NS   |
| T (ng/dL): m (SD)               | 4.16 (1.64)     | 4.79 (1.81)      | 4.54 (2.24)      | NS   | NS   | NS   | NS   |
| FAI (ng/dL): m (SD)             | 9.13 (3.24)     | 8.52 (3.2)       | 7.33 (3.83)      | NS   | NS   | 0.049 | NS   |
| E (pg/ml): m (SD)               | 22.83 (9.17)    | 21.33 (11.08)    | 27.18 (11.86)    | NS   | 0.43 | NS   | NS   |
| FEI (pg/ml): m (SD)             | 52.21 (25.64)   | 41.5 (25.9)      | 48.99 (27.37)    | NS   | NS   | NS   | NS   |
| β-CTX (ng/mL): m (SD)           | 0.379 (0.22)    | 0.47 (0.31)      | 0.67 (0.57)      | 0.003 | 0.048 | 0.002 | NS   |
| Osteocalcin (ng/mL): m (SD)     | 20.01 (10.23)   | 24.15 (22.53)    | 41 (55.67)       | 0.011 | 0.036 | 0.011 | NS   |
| 25(OH)D3 (ng/mL): m (SD)        | 18.59 (5.23)    | 21.4 (6.30)      | 21.22 (6.63)     | 0.041 | NS   | NS   | 0.048 |
| Lumbar spine BMD (g/cm²): m (SD)| 1.232 (0.187)   | 0.989 (0.115)    | 0.844 (0.12)     | <0.001 | <0.001 | <0.001 | <0.001 |
| Total hip BMD (g/cm²): m (SD)   | 1.07 (0.12)     | 0.89 (0.098)     | 0.699 (0.1)      | <0.001 | <0.001 | <0.001 | <0.001 |

Mean ± SD : m (SD) *: <0.05 **: < 0.001
One way analysis of variance + Tests Post hoc (Bonferroni)
p: osteoporosis-osteopenia-normal  p₁: osteoporosis – osteopenia p₂ : osteoporosis - normal p₃ : osteopenia - normal
LS_BMD  lumbar spine bone mineral density  TH_BMD  Total hip bone mineral density  FAI  Free androgen index  SHBG  Sex Hormones Binding Globulin
FEI   Free estrogen index  ALP   Alkaline phosphatase  PTHi Parathormone (PTH) intact  OC Osteocalcin
β-CTX Crosslaps  25(OH)D3  25-hydroxyvitamin D  BMI  Body mass index  E  Estradiol  T Testosterone
### Table 2: correlation between biochemical values and age, BMI and BMD (n=142)

|         | ALP  | PTHi | OC   | β-CTX | E   | T   | SHBG | FEI | 25(OH)D | Age | BMI |
|---------|------|------|------|-------|-----|-----|------|-----|---------|-----|-----|
| PTHi    | 0.237* |      |      |       |     |     |      |     |         |     |     |
| OC      | 0.252* | 0.666** |      |       |     |     |      |     |         |     |     |
| β-CTX   | 0.310* | 0.565** | 0.879** |       |     |     |      |     |         |     |     |
| E       | 0.110 | 0.283* | 0.257* | 0.234* |     |     |      |     |         |     |     |
| T       | 0.02  | 0.06  | 0.13 | 0.06  | 0.45** |     |      |     |         |     |     |
| SHBG    | 0.09  | 0.15  | 0.10 | 0.12  | 0.224* | 0.562** |     |     |         |     |     |
| FEI     | -0.04 | 0.07  | 0.07 | 0.02  | 0.557** | -0.13 | -0.53** |     |         |     |     |
| FAI     | 0.10  | 0.13  | -0.04 | 0.06  | 0.10  | -0.03 | 0.330** | -0.214** | -0.13 | -0.177* | -0.09 |
| 25(OH)D | -0.04 | -0.07 | 0.10 | 0.09  | 0.192* | 0.190* | 0.07  | 0.08  | 0.12    |     |     |
| Age     | 0.10  | 0.13  | -0.04 | 0.06  | 0.10  | -0.03 | 0.330** | -0.214** | -0.13 | -0.177* | -0.09 |
| BMI     | -0.09 | 0.01  | -0.173* | -0.211* | -0.12 | 0.339** | -0.253** | 0.13  | 0.05    | -0.177* | -0.09 |
| LS_BMD  | -0.12 | 0.02  | -0.06 | -0.13 | 0.05  | -0.03 | -0.220** | 0.15  | 0.189*  | -0.12 | -0.14 |
| TH_BMD  | -0.353* | -0.311** | -0.300** | -0.338** | -0.15 | -0.15 | -0.262** | 0.09  | 0.169*  | -0.06 | -0.261** |

*: <0.05  
**: < 0.001

### Table 3: multiple linear regression analysis with BMD as dependent variable (n=142)

|         | Bêta | SE   | p-value |
|---------|------|------|---------|
| TH_BMD  | 0.334 | 0.003 | <0.001  |
| BMI     | 0.360 | 0.004 | >0.001  |
| ALP     | -0.218 | <0.001 | 0.001   |
| PTHi    | -0.231 | <0.001 | 0.002   |
| AGE     | -0.174 | 0.001 | 0.015   |
| LS_BMD  | 0.171 | 0.005 | 0.020   |
| FAI     |      |      |         |

### Table 4: multiple logistic regression analysis with the presence of osteoporosis as dependent variable (n=142)

|         | Exp(B) | [95% Conf. Interval] | p-value |
|---------|--------|----------------------|---------|
| ALP     | 1.0255 | [1.0062-1.0453]     | 0.0096  |
| Age     | 1.0807 | [1.0172-1.1481]     | 0.0120  |
| BMI     | 0.8407 | [0.7293-0.9691]     | 0.0167  |
| Cigarette smoking | 1.8557 | [1.0488-3.2833] | 0.0337  |